| Title: |
A prospective multicenter feasibility study of a miniaturized implantable continuous flow ventricular assist device in smaller children with heart failure. |
| Authors: |
Almond, Christopher S; Davies, Ryan; Adachi, Iki; Richmond, Marc; Law, Sabrina; Tunuguntla, Hari; Mao, Chad; Shaw, Fawwaz; Lantz, Jodie; Wearden, Peter D; Jordan, Lori C; Ichord, Rebecca N; Burns, Kristin; Zak, Victor; Magnavita, Ashley; Gonzales, Selena; Conway, Jennifer; Jeewa, Aamir; Freemon, D 'Andrea; Stylianou, Mario; Sleeper, Lynn; Dykes, John C; Ma, Michael; Fynn-Thompson, Francis; Lorts, Angela; Morales, David; Vanderpluym, Christina; Dasse, Kurt; Patricia Massicotte, M; Jaquiss, Robert; Mahle, William T |
| Source: |
Department of Pediatrics |
| Publisher Information: |
LVHN Scholarly Works |
| Publication Year: |
2024 |
| Collection: |
Lehigh Valley Health Network: LVHN Scholarly Works |
| Subject Terms: |
Humans; Heart-Assist Devices; Feasibility Studies; Child; Preschool; Male; Infant; Female; Prospective Studies; Heart Failure; Miniaturization; Prosthesis Design; Treatment Outcome; United States; Department of Pediatrics; Medicine and Health Sciences; Pediatrics |
| Description: |
BACKGROUND: There is no FDA-approved left ventricular assist device (LVAD) for smaller children permitting routine hospital discharge. Smaller children supported with LVADs typically remain hospitalized for months awaiting heart transplant-a major burden for families and a challenge for hospitals. We describe the initial outcomes of the Jarvik 2015, a miniaturized implantable continuous flow LVAD, in the NHLBI-funded Pumps for Kids, Infants, and Neonates (PumpKIN) study, for bridge-to-heart transplant. METHODS: Children weighing 8 to 30 kg with severe systolic heart failure and failing optimal medical therapy were recruited at 7 centers in the United States. Patients with severe right heart failure and single-ventricle congenital heart disease were excluded. The primary feasibility endpoint was survival to 30 days without severe stroke or non-operational device failure. RESULTS: Of 7 children implanted, the median age was 2.2 (range 0.7, 7.1) years, median weight 10 (8.2 to 20.7) kilograms; 86% had dilated cardiomyopathy; 29% were INTERMACS profile 1. The median duration of Jarvik 2015 support was 149 (range 5 to 188) days where all 7 children survived including 5 to heart transplant, 1 to recovery, and 1 to conversion to a paracorporeal device. One patient experienced an ischemic stroke on day 53 of device support in the setting of myocardial recovery. One patient required ECMO support for intractable ventricular arrhythmias and was eventually transplanted from paracorporeal biventricular VAD support. The median pump speed was 1600 RPM with power ranging from 1-4 Watts. The median plasma free hemoglobin was 19, 30, 19 and 30 mg/dL at 7, 30, 90 and 180 days or time of explant, respectively. All patients reached the primary feasibility endpoint. Patient-reported outcomes with the device were favorable with respect to participation in a full range of activities. Due to financial issues with the manufacturer, the study was suspended after consent of the eighth patient. CONCLUSION: The Jarvik 2015 LVAD appears to ... |
| Document Type: |
text |
| Language: |
unknown |
| Relation: |
https://scholarlyworks.lvhn.org/pediatrics/2769; https://pubmed.ncbi.nlm.nih.gov/38713124/ |
| Availability: |
https://scholarlyworks.lvhn.org/pediatrics/2769; https://pubmed.ncbi.nlm.nih.gov/38713124/ |
| Accession Number: |
edsbas.EE8FCF70 |
| Database: |
BASE |